30 results on '"Wuttig, D."'
Search Results
2. Measurement and Control of Ultra-Low Liquid Flowrates for Drug Delivery Application
3. An integrated view on genetic and epigenetic mechanisms revealed aberrant DNA methylation as an important source for miRNA deregulation in prostate cancer: SW01.S2–61
4. Transkriptomweite Expressionsanalysen an pulmonalen Nierenzellkarzinommetastasen
5. In-vitro- und In-vivo-Evaluierung von inhibitorischen Nukleinsäurekonstrukten für eine spezifische Therapie des humanen Harnblasenkarzinoms
6. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases
7. Computer-aided immunofluorescence microscopy (CAIFM) for ANCA diagnostics
8. 569 DOWN-REGULATION OF PARK2 AND PACRG IN CLEAR CELL RENAL CELL CARCINOMA IS ASSOCIATED WITH TUMOUR AGGRESSIVENESS
9. 1027 GENE SIGNATURES OF PULMONARY RENAL CELL CARCINOMA (RCC) METASTASES REFLECT METASTASES-FREE INTERVAL AND NUMBER OF METASTASES OF THE PATIENT
10. T02-P-07 Sexual behavior and its changes in long-term partnerships
11. POS-02.13: siRNA-mediated multitarget inhibition of antiapoptotic BCL2, BCLXL and XIAP in bladder cancer cells
12. Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition?
13. 387 MULTITARGET SIRNA INHIBITION OF ANTIAPOPTOTIC GENES IN BLADDER CANCER CELLS
14. SIRNA-MEDIATED INHIBITION OF ANTIAPOPTOTIC GENES IN HUMAN BLADDER CANCER CELLS
15. THERAPEUTIC EFFECTS OF SIRNA MEDIATED INHIBITION OF DIFFERENT SURVIVIN TRANSCRIPTS IN BLADDER CANCER CELLS
16. POS-02.13: siRNA-mediated multitarget inhibition of antiapoptotic BCL2, BCLX L and XIAP in bladder cancer cells
17. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma
18. POS-02.13: siRNA-mediated multitarget inhibition of antiapoptotic BCL2, BCLXL and XIAP in bladder cancer cells
19. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.
20. PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome.
21. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.
22. microRNA biomarkers in body fluids of prostate cancer patients.
23. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.
24. A simple strand-specific RNA-Seq library preparation protocol combining the Illumina TruSeq RNA and the dUTP methods.
25. Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer.
26. Serum microRNAs as non-invasive biomarkers for cancer.
27. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient.
28. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells.
29. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.
30. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.